The Importance of Proactive End-of-Life Discussions in Oncology

Commentary
Video

Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.

Kelley A. Rone, DNP, RN, AGNP-c, spoke with CancerNetwork® about the challenges and strategies associated with end-of-life conversations and explored the need for proactive conversations in this space.

Rone, an advanced practice nurse in gastrointestinal cancer at the Mayo Clinic in Phoenix, Arizona, emphasized the need for physicians to acknowledge the potential limitations of treatment and to engage in open and honest discussions with patients about their prognosis. This strategy involves addressing the emotional and psychological impact of a terminal diagnosis and providing support for patients and their families as they navigate end-of-life care.

She also focused on barriers that may prevent physicians from initiating these conversations and offered potential solutions on how to overcome them.

Transcript:

We should all have [end-of-life] conversations. This is just my opinion: I think with the way our physicians are educated, they don’t spend a lot of time focusing on the fact that [their] treatment might fail. Maybe one of the difficulties is that a lot of physicians feel like, “Well, we should keep doing what we’re doing.” [This is] especially [true] in younger patients. We’re seeing more and more younger patients, and a lot of times the physicians will want to keep treating somebody because they’re young. “Well, we can’t quit now; they are so young.” Why do we need to [keep] younger people [on treatment] just because they’re young? If this scenario was occurring in someone who’s 78 vs 38 [years old], would you do the same thing for them?

Most of the oncologists that I work with are reasonably comfortable talking about this, but sometimes, it’s much more difficult for them based on the patient’s situation. I don’t know if you can make people okay with talking about death. Oncologists who are newer in the role may struggle with it a little bit more. As they become more seasoned, they become better at it. Some of the oncologists, though, are lovely, and I know they’re just not good at talking about death. With those oncologists, I [might say], “You should probably not have that conversation with the patient. I’ll take care of it.” If the patient is hearing it from all of us, that [the treatment] is not working, or this may not work at some point, then it’s much more easily accepted.

Recent Videos
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
Differences in pancreatic cancer responses to treatment elicits a need to better educate patients on expectations in treatment, particularly chemotherapy.
Increasing patient awareness of modifiable risk factors for pancreatic cancer may help mitigate incidence of pancreatic cancers.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Related Content